CME Webcast Discusses New Therapies for Lung Cancer

OSUWexnerbloglogo2014 CME Webcast Discusses New Therapies for Lung Cancer. On this CME webcast, we’re going to update you on the medical management of lung cancer and focus on non-small cell lung cancer. Joining our moderator in the studio is medical oncologist at the James Cancer Hospital and Professor of Internal Medicine from the Ohio State University, Dr. David Carbone.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: Review some of the latest practice-changing findings in the management of lung cancer; and Understand the basic principles of workup and initial lung cancer management decisions.

You’ll also learn about the following:

  • Classifying non-small cell lung cancer
  • Common side effects of driver-targeted therapies
  • What the primary care physician needs to know about co-managing patients taking driver-targeted therapy

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

 

Gain A Better Understanding of Psoriasis on CME Webcast

OSUWexnerbloglogo2014 Gain A Better Understanding of Psoriasis on CME Webcast. Over the centuries, thousands of treatments have been tried and thousands of treatments have failed. But the good news is that in the past few years there have been effective new biologic agents developed that are offering hope to patients with the most severe cases of psoriasis. Joining us on our webcast to discuss the diagnosis and management of psoriasis is dermatologist and Assistant Professor of Internal Medicine, Dr. Jessica Kaffenberger.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: RECOGNIZE the different types of psoriasis and how to effectively treat them; DESCRIBE the pathogenesis of psoriasis and how it correlates with the newest therapies; and IDENTIFY frequent psoriasis co-morbidities that affect medication management.

You’ll also learn about the following:

  • The etiology of psoriasis
  • New directions in treating psoriasis
  • The role of skin biopsy
  • Psoriasis versus eczema
  • Long-term prognosis for patients with psoriasis
  • Relationship of diet, exercise, and sunlight with psoriasis
  • Deodorants and common skin lotions
  • Swimming with psoriasis
  • Treatment of psoriatic arthritis
  • Precautions for patients taking methotrexate
  • Genital psoriasis and sexual health

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

CME Webcast Teaches on Immunosuppressant Medications

OSUWexnerbloglogo2014 CME Webcast Teaches on Immunosuppressant Medications. More and more, primary care physicians and hospitalists are finding themselves taking care of patients who have been started on immunosuppressant medication a transplant physician, rheumatologist, nephrologist, or pulmonologist. On this CME webcast, we’re going to tell you what you need to know about these medications, their side effects, and their complications. Let me introduce our guests. Dr. Brian Keller is a lung transplant pulmonologist and Assistant Professor Internal Medicine at The Ohio State University. And Pamela Burcham is a lung transplant specialty pharmacist from the OSU Wexner Medical Center.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: DISCUSS indications for immunosuppressive therapies; and DESCRIBE prophylaxis immunization, and pregnancy considerations for patients on Immunosuppressive therapy; UNDERSTAND the indications for individual immunosuppressants; and DESCRIBE the common adverse effects and monitoring parameters of the immunosuppressive medications.

You’ll also learn about the following:

  • Common indications for immunosuppressant medications
  • Commonly used immunosuppressant medications
  • Food safety for patients taking immunosuppressant medications
  • Pneumocystis jiroveci clinical presentation
  • Indications for TNF inhibitors
  • Infection risk of TNF inhibitors
  • Management of immunosuppressants in the perioperative period
  • Travel safety when taking an immunosuppressant
  • Bone health and corticosteroids
  • Eye health and corticosteroids
  • Monitoring for methotrexate-induced hepatotoxicity
  • Thiopurine methylytransferase
  • Cyclophosphamide

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

Diagnosing and Treating Coronary Artery Disease

OSUWexnerbloglogo2014 Diagnosing and Treating Coronary Artery Disease. On this CME Webcast, we’re going to be discussing coronary artery disease: how to diagnosis it and how to treat it medically. We’re pleased to welcome coronary disease experts, first from the Ohio State University Division of Cardiovascular Medicine, Assistant Professor of Internal Medicine Dr. Scott Maffett. Joining him, we have cardiologist and Assistant Professor of Internal Medicine from OSU, Dr. Kavita Sharma.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: IDENTIFY reasons to get ischemic assessment; and DETERMINE what ischemic assessment is appropriate for different clinical scenario.

You’ll also learn about the following:

  • Cardiac stress test options
  • Medical treatment of coronary artery disease
  • Choosing a cardiac stress test
  • Pharmacologic cardiac stress testing
  • Peri-operative use of beta blockers
  • Aspirin in adults without known coronary disease
  • Approach to the incidental coronary calcification
  • Common radiotracers used in cardiac stress testing
  • Choosing a pharmacologic agent for stress testing
  • Laboratory monitoring when patients are taking statins
  • Discontinuing statin therapy

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.